Genome Insight earns CAP accreditation for clinical genomic testing

Genome Insight announced on the 26th that its clinical laboratory specializing in whole-genome sequencing in San Diego, California, has received accreditation from the College of American Pathologists (CAP).

CAP accreditation is a program administered by the College of American Pathologists, an authoritative organization that certifies the quality of clinical laboratory testing in the United States. It evaluates whether clinical testing for patients meets the highest standards of quality control. Laboratories must pass a range of validation procedures, including tests of result accuracy, to receive accreditation.

Genome Insight’s San Diego clinical laboratory already received Clinical Laboratory Improvement Amendments (CLIA) certification, the U.S. laboratory standard, in 2023 and was providing whole-genome sequencing clinical diagnostic services to leading hospitals in the United States. The new CAP accreditation is seen as an important achievement that further demonstrates the company’s technical capabilities and excellence.

Stephanie Ferguson, Genome Insight’s Chief Clinical Operations Officer, said, “This CAP accreditation, earned following an evaluation of Genome Insight’s clinical laboratory, reflects our efforts to maintain a rigorous quality management system that meets international standards. Our ultimate goal is to contribute to the advancement of precision medicine through whole-genome sequencing (WGS).” She added, “We expect this accreditation to help Genome Insight expand its clinical diagnostic and whole-genome sequencing analysis services and accelerate personalized patient care.”

Genome Insight: https://genomeinsight.net/